Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

Sabrina T WiebeAndreas HuennemeyerWerner KadusMarkus GoettelAlen JambrecinaArmin SchultzRichard ViniskoLaura SchliekerLena HerichGerd Mikus

Published in: British journal of clinical pharmacology (2020)

Midazolam microdosing incorporated into early clinical studies is a feasible tool for reducing dedicated drug-drug interaction studies, meaning reduced subject burden. Limited sampling could further reduce subject burden, costs and needed resources.

Keyphrases

adverse drug
drug induced
emergency department
risk factors
finite element